Evidence map›Paper›PMID 33713325›Full record

ArticleNeurochemical research2021

Inhibition of TNFR1 Attenuates LPS Induced Apoptosis and Inflammation in Human Nucleus Pulposus Cells by Regulating the NF-KB and MAPK Signalling Pathway.

Feng Lv, Longbiao Yang, Jianxiu Wang, Zhixiang Chen, Qizhao Sun, Peiguo Zhang, Chentong Guan, Yanbin Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Feng Lv *Department of Pain, Zibo Central Hospital, No. 54 The communist youth league road, Zibo, 255000, Shandong Province, People's Republic of China. flveng@foxmail.com.
Longbiao Yang *Department of Orthopedics, ShanDong Energy ZiBo Mining Group Co.LTD. Central Hospital, Zibo, 255120, Shandong, People's Republic of China.
Jianxiu WangDepartment of Pain, Zibo Central Hospital, No. 54 The communist youth league road, Zibo, 255000, Shandong Province, People's Republic of China.
Zhixiang ChenDepartment of Orthopedics, ShanDong Energy ZiBo Mining Group Co.LTD. Central Hospital, Zibo, 255120, Shandong, People's Republic of China.
Qizhao SunDepartment of Orthopedics, ShanDong Energy ZiBo Mining Group Co.LTD. Central Hospital, Zibo, 255120, Shandong, People's Republic of China.
Peiguo ZhangDepartment of Pain, Zibo Central Hospital, No. 54 The communist youth league road, Zibo, 255000, Shandong Province, People's Republic of China.
Chentong GuanDepartment of Pain, Zibo Central Hospital, No. 54 The communist youth league road, Zibo, 255000, Shandong Province, People's Republic of China.
Yanbin LiuDepartment of Orthopedic Surgery, Liaocheng People's Hospital, Shandong First Medical University, 67 Dong Chang Xi Road, Liaocheng, 252000, Shandong, People's Republic of China. 2911756059@qq.com.
Central Hospital of Zibo · CNLiaocheng People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intervertebral disc degeneration (IDD) is accompanied by nucleus pulposus (NP) cell apoptosis, inflammation, and extracellular matrix degradation. Tumour necrosis factor receptor 1 (TNFR1) is a receptor of TNF-α, and is deeply involved in the processes of IDD. However, the effect of TNFR1 inhibition on IDD is not clear. Herein, we report that TNFR1 was increased in LPS-treated HNPCs. The aim of this study was to investigate the potential therapeutic effect of TNFR1 siRNA and selective antagonists of TNFR1 (GSK1995057) on HNPC damage. The results showed that the blockade of TNFR1 by TNFR1 siRNA and GSK1995057 effectively suppressed the cell viability loss, apoptosis, and inflammation induced by LPS in HNPCs. Furthermore, we found that TNFR1 siRNA and GSK1995057 inhibited activation of the NF-KB and MAPK signalling pathways in LPS-stimulated HNPCs. In summary, the blockade of TNFR1 effectively suppressed LPS-induced apoptosis and inflammation in HNPCs through the NF-KB and MAPK signalling pathways. This revealed that the blockade of TNFR1 may provide a potential therapeutic treatment for IDD.

Indexed as

Antibodies, Monoclonal, HumanizedApoptosisCells, CulturedCell SurvivalCytokinesExtracellular MatrixHumansInflammationLipopolysaccharidesMAP Kinase Signaling SystemNF-kappa B p50 SubunitNucleus PulposusReceptors, Tumor Necrosis Factor, Type IRNA, Small InterferingAntibodies, Monoclonal, HumanizedCytokinesGSK1995057LipopolysaccharidesNF-kappa B p50 SubunitNFKB1 protein, humanReceptors, Tumor Necrosis Factor, Type IRNA, Small InterferingTNFRSF1A protein, humanIntervertebral disc degenerationNucleus pulposus cellsTNFR1TNF-α

Identifiers

PMID33713325
OpenAlexW3135852499

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.